Human Genome Sciences Initiates Phase 3 Clinical Trial Of Albuferon(R) With Ribavirin In Patients With Chronic Hepatitis C Genotypes 2 And 3

Wed, 28 Feb 2007 02:00 PM EST

... Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has initiated dosing in ACHIEVE 2/3, a Phase 3 clinical trial of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in treatment-naive patients with chronic hepatitis C genotypes 2 and 3. [click link for full article] ...